{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:58:13Z","timestamp":1789001893330,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","heartrhythmjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hrthm.2016.12.010","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T09:31:21Z","timestamp":1481275881000},"page":"564-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-6559","authenticated-orcid":false,"given":"Simon","family":"Ermakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Gerstenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Svetlichnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin M.","family":"Scheinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2016.12.010_bib1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1253\/circj.CJ-15-0288","article-title":"Arrhythmogenic right ventricular dysplasia\/cardiomyopathy: three decades of progress","volume":"79","author":"Calkins","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.hrthm.2016.12.010_bib2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10557-015-6583-8","article-title":"Pharmacotherapy and other therapeutic modalities for managing arrhythmogenic right ventricular cardiomyopathy","volume":"29","author":"Rigato","year":"2015","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hrthm.2016.12.010_bib3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jacc.2007.03.049","article-title":"Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia\/cardiomyopathy","volume":"50","author":"Dalal","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2016.12.010_bib4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/pace.12250","article-title":"Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy","volume":"37","author":"Ermakov","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2016.12.010_bib5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1161\/CIRCEP.115.003562","article-title":"Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy","volume":"8","author":"Santangeli","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2016.12.010_bib6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/CIRCEP.111.968677","article-title":"Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia\/cardiomyopathy","volume":"5","author":"Philips","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2016.12.010_bib7","first-page":"1511","article-title":"Efficacy of the combination of low doses of beta-blockers and amiodarone in the treatment of refractory ventricular tachycardia","volume":"82","author":"Tonet","year":"1989","journal-title":"Arch Mal Coeur Vaiss"},{"issue":"Suppl D","key":"10.1016\/j.hrthm.2016.12.010_bib8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/eurheartj\/10.suppl_D.61","article-title":"Characteristics, prognosis and treatment of the ventricular arrhythmias of right ventricular dysplasia","volume":"10","author":"Leclercq","year":"1989","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2016.12.010_bib9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/01.CIR.86.1.29","article-title":"Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia","volume":"86","author":"Wichter","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2016.12.010_bib10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00059-005-2677-6","article-title":"Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?","volume":"30","author":"Wichter","year":"2005","journal-title":"Herz"},{"key":"10.1016\/j.hrthm.2016.12.010_bib11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.yjmcc.2009.10.005","article-title":"Flecainide inhibits arrhythmogenic Ca2 waves by open state block of ryanodine receptor Ca2 release channels and reduction of Ca2 spark mass","volume":"48","author":"Hilliard","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.hrthm.2016.12.010_bib12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.hrthm.2016.12.010_bib13","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","article-title":"Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"57","author":"Van der Werf","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2016.12.010_bib14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","article-title":"Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy","volume":"14","author":"Van der Zwaag","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hrthm.2016.12.010_bib15","unstructured":"Roberts JD, Wright PJ, Makara M, etal. Pathog enic ankyrin-Bmutation and exercise: a novel gene-environment interaction predisposing to arrhythmogenic right ventricular ardiomyopathy. Heart Rhythm Society 2015 national meeting (May 13-16, 2015) in Boston, MA. Abstract presented in Section AB23"},{"key":"10.1016\/j.hrthm.2016.12.010_bib16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.cardiores.2006.04.004","article-title":"Composite polymorphisms in the ryanodine receptor 2 gene associated with arrhythmogenic right ventricular cardiomyopathy","volume":"71","author":"Milting","year":"2006","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2016.12.010_bib17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0167-5273(99)00142-4","article-title":"Risk stratification of sudden cardiac death and malignant ventricular arrhythmias in right ventricular dysplasia-cardiomyopathy","volume":"71","author":"Peters","year":"1999","journal-title":"IntJ Cardiol"},{"key":"10.1016\/j.hrthm.2016.12.010_bib18","series-title":"Arrhythmogenic Right Ventricular Dysplasia\/Cardiomyopathy","first-page":"45","article-title":"Risk. Stratification and antiarrhythmic drug therapy","author":"Wichter","year":"2007"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527116311663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527116311663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T07:06:22Z","timestamp":1568617582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527116311663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1547527116311663"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2016.12.010","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2016.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}